Research programme: gene-activated human growth hormone - Takeda
Latest Information Update: 16 Jan 2019
At a glance
- Originator Shire Pharmaceuticals Group
- Developer Shire
- Class Growth hormones
- Mechanism of Action Somatotropin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Short stature
Most Recent Events
- 08 Jan 2019 Shire was acquired and merged into Takeda
- 28 Jul 2005 Transkaryotic Therapies has been acquired and merged into Shire Pharmaceuticals Group
- 19 Jul 2004 This programme is available for licensing(http://www.tktx.com)